SEC Form 4 · accession 0001765581-19-000012
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew P. Young
Officer — EVP & CFO
Period of report
Feb 25, 2019
Accepted (ET)
Feb 27, 2019 · 8:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2 | Feb 25, 2019 | F | 1,218 | $126.25 | D | 30,917 | D | |
| Ordinary Shares | Feb 26, 2019 | S | 1,032 | $125.93 | D | 29,885 | D | |
| Ordinary Shares | Feb 26, 2019 | F | 1,034 | $127.76 | D | 28,851 | D | |
| Ordinary Shares | Feb 27, 2019 | S | 884 | $137.91 | D | 27,967 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
- F2Includes 67 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2018.
- F3This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.